Posted by Michael Wonder on 09 Jul 2020
Drugmakers appeal limited insurance benefit for dementia drug choline alfoscerate
9 July 2020 - Sixty-six manufacturers of choline alfoscerate, a dementia drug, filed an appeal to the Health Insurance Review and Assessment Service (HIRA), protesting the agency’s recent decision to limit the national health insurance benefit for the medication.
According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), the 66 sellers of choline alfoscerate released the appeal statement on Wednesday.
On June 11, HIRA held a meeting of the Health Insurance Drug Reimbursement Committee and decided that choline alfoscerate would receive the national health insurance benefit only for severe and general dementia. For other indications, choline alfoscerate will get a “selected reimbursement” where the patient pays 80 percent of the cost, instead of the current 30 percent, HIRA said.
